As CAR T-cell therapy has become a transformative option in multiple myeloma, a first-of-its-kind trial now extends that potential to relapsed/refractory light chain (AL) amyloidosis. At the recent ...

Researchers show for the first time that engineered human plasma B cells can be used to treat a disease -- specifically leukemia -- in a humanized animal model. The results mark a key step in the ...

An experimental AstraZeneca (NASDAQ:AZN) drug, anselamimab, failed to extend survival or cut heart-related hospitalizations in patients with a rare plasma cell disorder, disappointing hopes it could ...

Plasma is irradiated from a non-thermal atmospheric-pressure plasma device onto a mammalian cell culture medium to produce PAM. Plasma-activated medium (PAM) shows tumor-fighting effects against the ...

This article and associated images are based on a poster originally authored by Mette Juul Jacobsen, Anastasios Glaros, Abrahan Hernandez-Hernandez, Anja Mezger, Tina Friis, and Peter Mouritzen and ...

MRI lesion burden as a predictor of progression and survival in smoldering multiple myeloma. Neoadjuvant (neoadj) osimertinib (osi) ± chemotherapy (CT) vs CT alone in resectable (R) epidermal growth ...

Evaluation of daratumumab for treating multiple myeloma in patients with high-risk cytogenetic factors: A pooled analysis using synthetic individual patient data. This is an ASCO Meeting Abstract from ...

Cell culture materials impact a target cell’s ability to proliferate and function as planned. These materials offer precise mechanical and chemical cues that decide a cell's morphology and ...